A systematic review of five trials suggested more durable sleep benefits from CBT-I. Its short-term medication comparison rested on very low-grade evidence.
The reviewers searched four databases for randomized comparisons of cognitive behavioral therapy for insomnia with medications and assessed evidence quality using GRADE. Quantitative sleep outcomes were required for inclusion.
Low- to moderate-grade evidence favored CBT-I over benzodiazepine and non-benzodiazepine drugs in the longer term. Evidence suggesting greater short-term benzodiazepine effectiveness was rated very low grade.
Only five studies qualified. The review noted limited evidence for patients with secondary or comorbid insomnia and a lack of comparisons with common off-label medicines. Behavioral treatment also cannot be fully blinded in the same way as identical tablets.
Durability beyond the observed follow-up and applicability to different clinical populations remained uncertain.
Distinguish immediate symptom relief from persistence of benefit after treatment. A better long-term average does not mean medication never helps or that every patient can access or complete CBT-I. The review supports discussing treatment time horizons and evidence quality rather than presenting one approach as conclusively superior for every insomnia presentation.
Original analysis of the supplied journal article, identified as PMC3481424.